Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR23303748

—

38ddf241-357f-52bd-9d0d-85dffbfc5983

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • COAGULATION+0.420
  • HEDGEHOG_SIGNALING+0.420
  • KRAS_SIGNALING_DN+0.390
  • MYOGENESIS+0.390
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
  • APICAL_SURFACE+0.350
  • ANGIOGENESIS+0.330
  • ALLOGRAFT_REJECTION+0.290
  • IL6_JAK_STAT3_SIGNALING+0.280
  • INFLAMMATORY_RESPONSE+0.260

Top 10 suppressed

  • MYC_TARGETS_V1-0.710
  • E2F_TARGETS-0.670
  • G2M_CHECKPOINT-0.650
  • MYC_TARGETS_V2-0.600
  • MTORC1_SIGNALING-0.490
  • PROTEIN_SECRETION-0.480
  • UNFOLDED_PROTEIN_RESPONSE-0.480
  • DNA_REPAIR-0.450
  • MITOTIC_SPINDLE-0.390
  • PI3K_AKT_MTOR_SIGNALING-0.360

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1467011
brain-umap@2
GTEX—0.931
2TCGA-55-8619-01A-11R-2403-07
lung-landscapes@6
—cohortA10.924
3TCGA-55-8621-01A-11R-2403-07
lung-landscapes@6
—cohortA10.920
4SRR2665516
melanoma-umap@29
——0.915
5sclcMAD11162_S44.txt
lung-landscapes@6
—cohortA10.912
6SRR33532813
breast-umap@18
—A0.907
7SRR598276
brain-umap@2
GTEX—0.907
8SRR817775
brain-umap@2
GTEX—0.907
9DRR168582
bladder-landscape@3
——0.906
10TCGA-L4-A4E6-01A-11R-A24H-07
lung-landscapes@6
—cohortA10.905

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
COAGULATION0.420Binimetinib— uncovered
HEDGEHOG_SIGNALING0.420Inavolisib— uncovered
KRAS_SIGNALING_DN0.390Remibrutinib— uncovered
MYOGENESIS0.390Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.380Inavolisib— uncovered
APICAL_SURFACE0.350Temsirolimus— uncovered
ANGIOGENESIS0.330Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.290Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.280Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.260Idelalisib— uncovered
PANCREAS_BETA_CELLS0.260Cobimetinib— uncovered
BILE_ACID_METABOLISM0.250Inavolisib— uncovered
KRAS_SIGNALING_UP0.250Inavolisib— uncovered
IL2_STAT5_SIGNALING0.240Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.220Inavolisib— uncovered
COMPLEMENT0.190Inavolisib— uncovered
APICAL_JUNCTION0.180Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.160Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.100Inavolisib— uncovered
FATTY_ACID_METABOLISM0.070Inavolisib— uncovered